<!DOCTYPE html>
<html lang="en">
<head>	
	<meta charset="UTF-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="viewport" content="width=device-width, initial-scale=1.0">
	<title>Email</title>

	<style type="text/css">
		body {
			margin: 0;
			background-color: black;
		}
		table {
			border-spacing: 0;
			max-width: 600px;
		}
		img {
			border: 0;
			display: block;
			margin-left: auto;
			margin-right: auto;
		}
		.wrapper {
			width: 100%;
			table-layout: fixed;
			background-color: black;
		}
		.webkit {
			max-width: 600px;
		}
		.outer{
			Margin: 0 auto;
			width: 100%;
			background-color: black;
		}
		.two-columns{
			text-align: center;
			font-size: medium;
			padding: 40px 0;		
		}
		
		@media screen and (max-width: 600px) { 
	
		}
	</style>
</head>
<body>
	<body>
		<center class="wrapper">
			<div class="webkit" >
					<table class="outer">
							<tr>
								<td >
									<table width="100%" style="border-spacing: 0;">
										<tr style="font-family: Arial;">
											<td style="font-size:5px" >
												<h1 style="color: white;" >Email</h1>
											</td>
										</tr>
									</table>
								</td>
							</tr>
							<tr style="height: 50px;">
								<td style="background-color: white;" >

								</td>
							</tr>
								<td > 
									<table  style="background-color: white;" width="100%" style="border-spacing: 0;" >
										<tr >		
											<td style="padding-left: 30px;" style="background-color: white;">
												<p style="color:#b5b5b5"><b>From:</b> DiscoverTIL@iovance.com</p>
												<p style="color:#b5b5b5"><b>Subject line:</b></p>
												<p style="color:#b5b5b5">Discover the science of tumor infiltrating lymphocytes (TIL) at DiscoverTIL.com</p>
												<p style="color:#b5b5b5">Alt: Find out about the science of tumor infiltrating lymphocytes (TIL) in multiple </p>
												<p style="color:#b5b5b5">solid tumors</p>
												<p style="color:#b5b5b5">Alt: Explore how tumor infiltrating lymphocytes (TIL) work naturally in the body</p>
											</td>
										</tr>
									</table>
								</td>
							</tr>
							<tr style="background-color: white;">
								<td >
									<table style="width: 600px;" >
											<td ></td>
												<img style="display:block;" width="100%" height="100%" src="images/discover1.PNG" />
											</td>
											
									</table>
								</td>
							</tr>
							<tr style="background-color: white;">
								<td style="padding-left: 50px;"> 
									<table style="line-height: 5px;" >
										<td style="font-size: 22px;">
										<p style="color:#003a5d">Tumor infiltrating lymphocytes (TIL) are part of the body’s </p>
										<p style="color:#003a5d">natural response to cancer. For patients who have not </p>
										<p style="color:#003a5d">responded to or who have progressed on immune </p>
										<p style="color:#003a5d">checkpoint inhibitors, TIL are being investigated as a </p>
										<p style="color:#003a5d">potential treatment option in multiple solid tumors.1-3</p>
										</td>
									</table>
								</td>
							</tr>
							<tr style="background-color: white;">
								<td style="align-self: stretch;"> 
									<table >
										<img  src="images/Science1.PNG" alt="center">
									</table>
								</td>
							</tr>
							<tr style="background-color: white;">
								
								<td style="font-size: 20px;" align="justify"> 
									<table style="padding-left: 50px;" >
										<p style="color:#003a5d">IOVANCE Biotherapeutics is committed to deepening the </p>
										<p style="color:#003a5d">understanding of TIL and optimizing TIL technology to help </p>
										<p style="color:#003a5d">shape the next chapter of TIL cell therapy.</p>
									</table>
								</td>
							</tr>
							<tr style="background-color: white;">
								<td> 
									<table >
										<img  src="images/Science2.PNG" alt="center">
									</table>
								</td>
							</tr style="max-width:100%">
							<tr style="background-color: white;">
								<td style="line-height: 5px;"> 
									<table style="padding-left: 50px;" >
										<p style="color:#54585a"> <b>References: 1.</b> Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive </p>
										<p style="color:#54585a"> immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. </p>
										<p style="color:#54585a"> 1986;233:1318-1321. <b>2.</b> Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint </p>
										<p style="color:#54585a"> inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):165.      </p>
										<p style="color:#54585a"> <b>3.</b> Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 </p>
										<p style="color:#54585a"> blockade. Cancer J. 2018;24(1):47-53. </p>
									</table>
									
								</td>
							</tr >
							<tr>
							<table style="max-width: 600px;" cellspacing="0" cellpadding="0" border="0">
								<tr style="background-color: white;">
									<td><img src="images/logo.PNG" style="display: block; margin: 0; padding:0; "></td>

									<td style="width: 100%;" style="line-height: 10px;">

										<p style="color:#383b43"> CONTACT US | PRIVACY POLICY | UNSUBSCRIBE</p>
										<p style="color:#383b43"> Iovance Biotherapeutics</p>
										<p style="color:#383b43"> 999 Skyway Rd</p>
										<p style="color:#383b43"> Suite 150 </p>
										<p style="color:#383b43"> San Carlos, CA 94070</p>
										<p style="color:#383b43"> © 2020 IOVANCE Biotherapeutics, Inc. All Rights Reserved.</p>
										<p style="color:#383b43"> IOVANCE logo is a trademark owned by Iovance </p>
										<p style="color:#383b43">Biotherapeutics, Inc. </p>
										<p style="color:#383b43"> PRC-US-00032(v1.0)</p>
							
									</td>

								</tr>
							</table>

							</tr>














					</table>
			</div>
		</center>	
	</body>

	

		



































	
</table>		
</body>
</html>